SCHEMBL503526

SCHEMBL503526

COC(=O)C(C)(N)Cc1ccc(O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.67
ESR1 P03372 6/20 0.50
ESR2 Q92731 5/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 2/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
EGFR P00533 1/20 0.45
CYP1A2 P05177 1/20 0.45
FYN P06241 1/20 0.45
POLB P06746 1/20 0.45
CYP3A4 P08684 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
APEX1 P27695 1/20 0.45
ADRA1A P35348 1/20 0.45
PTGS2 P35354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL540243 1.00 BLM (0.67) BLMESR1ESR2MEN1KMT2A
SCHEMBL503525 1.00 BLM (0.67) BLMESR1ESR2MEN1KMT2A
Hydrochloric Acid SCHEMBL540242 0.98 BLM (0.65) BLMESR1ESR2MEN1KMT2A
Hydrochloric Acid SCHEMBL540244 0.98 BLM (0.65) BLMESR1ESR2MEN1KMT2A
Hydrochloric Acid SCHEMBL1322060 0.98 BLM (0.65) BLMESR1ESR2MEN1KMT2A
SCHEMBL180210 0.85 BLM (0.47) BLMMEN1KMT2AKDM4EUSP2
SCHEMBL3647847 0.85 BLM (0.65) BLMESR1ESR2MEN1KMT2A
SCHEMBL31195654 0.85 BLM (0.47) BLMMEN1KMT2AKDM4EUSP2
SCHEMBL180265 0.85 BLM (0.47) BLMMEN1KMT2AKDM4EUSP2
SCHEMBL4610735 0.85 BLM (0.65) BLMESR1ESR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114599352-A alpha-methyl-DL-tyrosine alkyl esters for the treatment of cancer 迪美公司 2022-06-07 CN claimed
WO-2021076723-A1 ALKYLESTERS OF ALPHA-METHYL-DL-TYROSINE FOR USE IN TREATING CANCER TYME, INC. (US) 2021-04-22 WO claimed
US-20210106549-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS TYME, INC. 2021-04-15 US claimed
CN-114599352-A alpha-methyl-DL-tyrosine alkyl esters for the treatment of cancer 迪美公司 2022-06-07 CN disclosed
US-11352316-B2 Opioid receptor modulators and products and methods related thereto EPIODYNE, INC. (US) 2022-06-07 US disclosed
WO-2022048922-A1 SUBSTITUTED VICINAL DIAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF PAIN Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) 2022-03-10 WO disclosed
US-20210163402-A1 OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO EPIODYNE, INC. 2021-06-03 US disclosed
WO-2021076723-A1 ALKYLESTERS OF ALPHA-METHYL-DL-TYROSINE FOR USE IN TREATING CANCER TYME, INC. (US) 2021-04-22 WO disclosed
US-20210106549-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS TYME, INC. 2021-04-15 US disclosed
US-20140309424-A1 DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18F] FLUOROMETHYL) TYROSINE PIRAMAL IMAGING SA (CH) 2014-10-16 US disclosed
US-20140309424-A1 DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18F] FLUOROMETHYL) TYROSINE PIRAMAL IMAGING SA (CH) 2014-10-16 US disclosed
US-6071912-A INHIBIT HUMAN FACTOR XA AND ARE THEREFORE USEFUL AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY; AMINO-, OXY- AND THIA-SUBSTITUTED TRIAZINES BERLEX LABORATORIES, INC. (US) 2000-06-06 US disclosed
US-5994375-A ANTICOAGULANTS BERLEX LABORATORIES, INC. (US) 1999-11-30 US disclosed
CN-1199049-A Novel dipeptide derivatives and sweetening agents AJINOMOTO KK (JP) 1998-11-18 CN disclosed
CN-1199049-A Novel dipeptide derivatives and sweetening agents AJINOMOTO KK (JP) 1998-11-18 CN disclosed
US-4138484-A CHLORPROMAZINE OR THORIDAZINE WITH G-HYDROXYBUTYROLACTONE NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1979-02-06 US disclosed
US-4134991-A PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS, NEUROLEPTIC AGENTS SYNTHELABO (FR) 1979-01-16 US disclosed
US-4129652-A CHLORPROMAZINE OR THIORIDAZINE AND 5-ETHYL-5-PHENYL-2-PYRROLIDONE OR 1-HYDROXY-3-AMINO-2-PYRROLIDONE OR SALTS NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1978-12-12 US disclosed
US-4084000-A NEUROLEPTIC, GAMMA-AMINOBUTYRIC ACID DERIVATIVES NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1978-04-11 US disclosed
US-3978216-A AMINOOXYACETIC ACID NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352316-B2 Opioid receptor modulators and products and methods related thereto OPRM1, OPRD1, OPRK1 BLM 4370/4885ESR1 397/4885ESR2 308/4885
US-20210163402-A1 OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO OPRM1, OPRD1, OPRK1 BLM 4370/4885ESR1 397/4885ESR2 308/4885
US-20140309424-A1 DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18F] FLUOROMETHYL) TYROSINE TH, TYR, FTO BLM 4322/4885ESR1 1482/4885ESR2 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.